Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Inclusion Criteria: * Have a diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (NSCLC). * Have uni-dimensionally measurable and/or evaluable advanced NSCLC. * Have Stage IV or recurrent disease following radiation therapy. * Have ECOG performance status of 0-1 or Karnofsky performance status of 80- 100 at study entry. * Have given signed informed consent. * Be at least 18 years of age. * Have ANC greater than or equal to 1,500/mm3, platelets greater than or equal to 100,000/mm3, WBC greater than or equal to 3,000 mm3, and hemoglobin greater than or equal to 9 g/dL. * Have total bilirubin less than or equal to 1.5 x upper limits of normal, Alk Phos, AST and ALT less than or equal to 2.5 x upper limits of normal. * Have serum creatinine less than or equal to 1.5 mg/dL, or calculated creatinine clearance greater than or equal to 60 cc/minute. * Be disease free from a previously treated malignancy for more than three years. Patients with a history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded. * Agree to use effective contraception if procreative potential exists. * Must have positive EGFr expression (tumor tissue) by immunohistochemical assay. Exclusion Criteria: * Have received prior murine monoclonal antibody or Cetuximab therapy. * Have disease amenable to curative surgery. * Have received prior chemotherapy. * Have received radiation therapy within 3 weeks prior to the first infusion of Cetuximab. * Have a history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities, in the judgment of the PI. * Have uncontrolled seizure disorder, active neurological disease, or Grade 2 or higher neuropathy. * Be pregnant or breast-feeding. * Have received any investigational agent(s) within 1 month of study entry.